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Abstract
Background: Routine mammography improves survival. To achieve health benefits, women must attend breast
screening regularly at recommended time intervals. Maltese women are routinely invited to undergo mammography at
three-year intervals at an organized breast screening programme (MBSP) or can opt to attend a private clinic. Previous
research shows that health beliefs, particularly perceived barriers, were the most significant predictors of uptake to the
first MBSP invitation. Whether these beliefs and other factors are predictive of adherence with recommended time
intervals for mammography at organized or private screening in Malta is unknown. For the first time, this paper explores
the predictors for Maltese women screened within or exceeding the recommended three-year frequency in organized or
private screening in Malta.
Methods: Information was obtained from a cross-sectional survey of 404 women, aged 50 to 60 years at the time of their
first MBSP invitation, where women’s characteristics, knowledge, health beliefs and illness perceptions were compared.
The main variable of interest was women’s mammography attendance within a three-year interval (ADHERENT) or
exceeding three years (NON-ADHERENT). Data were analysed using descriptive statistics, chi-square test, Mann Whitney
test, Independent Samples t-test and Shapiro Wilk test.
Results: At the time of the survey, 80.2% (n = 324) had been screened within three years (ADHERENT), 5.9% (n = 24) had
exceeded the three-year frequency (NON-ADHERENT) while 13.9% (n = 56) never had a mammogram. No significant
associations were found between ADHERENT or NON-ADHERENT women in relation to sociodemographic or health
status variables (p > 0.05). Knowledge of screening frequency was significantly associated with women’s mammography
adherence (χ2 = 5.5, p= 0.020). Health beliefs were the strongest significant predictors to describe the variance between
ADHERENT and NON-ADHERENT screeners. When Mann Whitney test and Independent Samples t-test were applied on
mammography adherence, perceived barriers and cues to action were found to be the most important predictors
(p = 0.000, p = 0.039 respectively).
Conclusions: To increase routine and timely mammography practices, women who are non-adherent to recommended
time frequency guidelines should be targeted, together with their health beliefs, predominantly perceived barriers and
cues to action.
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Background
Breast cancer (BC) is the most common cancer among
women worldwide [1, 2]. The World Health Organization
(WHO) has identified prevention, early detection and
managing the cancer trajectory as the three pillars in the
reduction and control of the global cancer burden [3].
Based on global evidence from randomized controlled
trials [4, 5], early detection through mammography
screening has been documented to significantly decrease
BC mortality rates [6–8], and can lead to early treatment
and reduce its negative side-effects [9].
In Malta, BC is the most common type of cancer
among women. Around 280 cases have been diagnosed
each year in the last decade [10] with the Maltese nation
ranking 18th place with the highest incidence of BC in
2012 (85.9 per 100,000) [11]. The Maltese Breast Screen-
ing Programme (MBSP) was established in 2009 for
women aged 50–60 years every three years [12] and has
now expanded its age range to include women aged 61–
67 years. Prior to the MBSP, women in Malta could use
private mammography (there are currently 7 private
practices offering mammography in Malta).
Despite the availability of the MBSP, a number of
women still do not attend for mammography at the MBSP
or may not attend at recommended intervals. This is evi-
denced by data from our national cross-sectional survey
[13] showing that the uptake rate for first round BS at the
MBSP was lower than the European target rate of 70% [9],
and similarly for re-attendance, evidenced in our pilot
study on the second BS round in Malta [14]. These pro-
grammes can only be effective and indeed cost-effective
[15] if the attendance of the target screening population is
consistent with recommended intervals [16–18] in order
to achieve health benefits [8, 16, 19].
Currently, organized breast screening (BS) pro-
grammes are offered for free to asymptomatic women by
many countries in Western Europe and North America
[20], with time intervals between mammograms depend-
ing on the varying recommendations of various coun-
tries [21]. In Europe, the EU Council recommends a
two-year interval to women aged 50–69 years [9, 22].
However, countries implement these recommendations
as they consider fit [20]. For instance, Norway adheres
to the recommended EU thresholds, while a biennial
nationwide screening programme for women aged 50–
75 is offered in the Netherlands [23] and regionally orga-
nized screening programmes are offered in Switzerland
for women over 50, with the age limit varying between
69 and 74 years [24]. Notable exception for the screen-
ing interval is by United Kingdom and Malta who opted
for a three-yearly screening frequency [25].
Substantial disparity remains to date across countries
on attendance at regular time intervals [2] with recent
and regular attendance being studied less often than
initial attendance [17, 26, 27]. For instance, the more
privatized system in the United States may enable less
access to mammography than the social health care sys-
tem found in the United Kingdom [28], suggesting that
national context is important and worth exploring. The
Maltese National Health System (NHS) adopts a mixed
model approach comprising elements from both the
public (organized) and private sectors and this is one
possible reason for non-participation in the organized
screening programme (MBSP) or non-attendance at rec-
ommended intervals. Prior to the MBSP rollout across
Malta, asymptomatic women could self-refer privately
for mammography and symptomatic women were re-
ferred by a general practitioner (GP), breast surgeon or
gynaecologist either to the public symptomatic breast
unit or to the private sector for mammography. Despite
having the availability and efficiency of nationally-
organised screening programmes, some women may still
opt for the service privately and are considered asymp-
tomatic attendees to opportunistic screening [29, 30] but
are non-compliant in the context of invitation-based BS
[27]. Similarly, screening mammograms taken and read
in private clinics [30] remain widely used in America
and in European countries such as France, Luxembourg
and Switzerland [30–33].
To date, we are not aware of any study that has ex-
plored attendance to mammography screening according
to recommended time-intervals at organized or private
practices. Therefore, in order to understand if Maltese
women are adherent with recommendations for BS, we
analysed primary survey data in an effort to describe the
adherence rates. Hence, in order to analyse the differ-
ences between timely mammography adherence and
non-adherence to current time interval recommenda-
tions (three-year interval), we explored several determi-
nants, mainly health beliefs and illness perceptions. We
built on the findings of our prior study [13] which sug-
gests that health beliefs and illness perceptions vary be-
tween women who accept or refuse a BS invitation to
the organized programme. ‘Strengthening the Reporting
of Observational Studies in Epidemiology’ (STROBE)
guidelines [34] [see Additional file 1], have guided the
study findings in this article. This study will help to in-
form public health experts, policy-makers and screening
management to tackle regulated routine attendance in
their population-based screening programmes.
Theoretical framework
Health beliefs
Health behaviour takes place when a threat is recognized
as a result of a health problem [35] and is manipulated
by the individual’s perception of that threat [36]. The
Health Belief Model (HBM) has often been recom-
mended when dealing with behaviours that evoke illness,
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such as BC [37], and is thus an excellent fit for address-
ing the health beliefs and perceptions of BS among
women. The HBM consists of the following six main
variables: perceived susceptibility, perceived severity,
perceived benefits, perceived barriers, cue to action, and
self-efficacy [38]. Individuals will take action to prevent,
to screen for, or to control BC if they perceive them-
selves to be susceptible to the condition, if they believe
in the seriousness of the potential consequences, if they
believe the course of action would reduce their suscepti-
bility to or the severity of the condition, and if they be-
lieve that the anticipated benefits to taking the action
outweigh the barriers [38]. Based on the HBM, engaging
in mammography will be predicted by women’s percep-
tions about BC derived from their knowledge about the
disease [39]. Thus, it is significant for healthcare pro-
viders to increase knowledge through education about
BC and the importance and benefits of BS such as early
detection, reduced mortality and improved survival.
Several researchers have used standardized measures
of HBM constructs, such as Champion’s HBM scales for
mammography screening (CHBMS-MS) [35, 40, 41] in
order to determine the relationships between health beliefs
and health behaviours. These scales have been translated
and tested for reliability and validity in diverse populations
such as Iranian [40], Lithuanian [42], Malaysian [43], Arabic
[44], Korean [45], Chinese-Australian [46], African-
American [47], Spanish-speaking American women [48]
and Spanish women [41]. However, the variation in BS
behaviours is limitedly explained through HBM, since the
impact of emotions (such as fear) [49] is not considered,
nor does it accommodate social and environmental influ-
ences of past behaviour [50]. This is why other models,
such as the Common-Sense Model (CSM) of self-
regulation, have been utilised to understand BS uptake [51]
and to explain the variations in physical and psychological
adjustment to BC and disease outcomes [52, 53].
Illness perceptions
According to the Common-Sense Model (CSM), illness
perceptions are related to the cognitive (i.e. beliefs,
thoughts, ideas) and emotional (i.e. feelings) representa-
tions derived from the experience of an illness or illness-
related symptoms [54]. Each individual is known to have
his/her own beliefs about health / illness due to similar
but unique experiences [55]. Hence, an individual’s be-
haviour can be affected by the assessment of symptoms
and knowledge, beliefs and risk perceptions [56]. In re-
gard to healthy people, illness perceptions can serve as
guides for behaviour in relation to prevention [57] and
appear to be precursors of screening behaviour [56].
The utility of the CSM has been extensively investi-
gated quantitatively following the development of a
questionnaire, the Illness Perception Questionnaire
(IPQ) [58], which addresses the following five key di-
mensions: symptoms and names (identity), severity of
pain and impact on life functions (consequences), ex-
pected duration or expected age of onset (timeline),
whether the disease was perceived as preventable,
curable, or controllable (control/cure) and infection or
genetics (internal and external causes), in Leventhal’s
self-regulatory model [59]. Following advancement in
theory and measurement of the constructs related to the
CSM, the IPQ has been revised, expanded and renamed
as IPQ-R [60] with the inclusion of new dimensions,
such as the illness coherence scale in order to better
evaluate the overall meaning of the illness for the
patient. In addition, the content of the original cure/con-
trol component from the IPQ was treated separately in
the IPQ-R as the ‘personal control’ scale i.e. about per-
sonal abilities to control the illness and ‘treatment con-
trol’ scale i.e. the efficacy of treatment to cure or manage
the illness [61]. Also, the timeline dimension was differ-
entiated into two: (a) timeline (acute/chronic) i.e. beliefs
about the relative chronicity of the illness and (b) time-
line (cyclical) i.e. beliefs about the fluctuation in symp-
toms and temporal illness changeability [57]. An
important inclusion in IPQ-R was the measure of
emotional representations (related to the cognitive com-
ponents of illness representations) [57, 60].
Methods
The full details of the methods are described in detail
elsewhere [13]. In brief, a cross-sectional survey was
undertaken in Malta in 2015 and data were drawn retro-
spectively from a nationally representative sample of eli-
gible women (n = 404 with 95% confidence level and a
5% significance level), aged 50–60 years at the time of
their first invitation at the MBSP with no personal
history of BC. From our total sample, 60% were
attendees (n = 243) to breast screening and 40% were
non-attendees (n = 161) to the first call. This is an actual
representation of the uptake to the first screening invita-
tion. From every sub-population, the sample was se-
lected by stratified random sampling, i.e. stratified based
on district and age to give a true representation based
on the demographics of attendance and non-attendance
to the first screening round. Hence, all individuals were
selected at random based on the above percentages and
stratification.
Screening mammography uptake in the past three
years was self-reported for women who opted to go
privately but for those who had attended the MBSP, at-
tendance or non-attendance was verified through
screening records. Participation was voluntary and verbal
informed consent was obtained by telephone by a re-
search assistant. Full recruitment details are described in
our prior paper [13]. In order to carry out the study
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according to our methods and consent procedure, for-
mal ethical approval was sought and obtained from the
School Research Ethics Committee at the University of
Stirling (SREC14/15-Paper No.18v4) and from the
Maltese Health Ethics Committee (HEC 02/2015).
Measures
Based on previously validated questionnaires (CHBMS-
MS and IPQ-R) [35, 60], our study instrument, a 121-item
questionnaire was initially translated from English into the
Maltese language, adapted and pilot-tested among Maltese
women [62] after securing written permission from the re-
spective authors. A full description of the measures has
been published in a previous article [13].
Classification of variables
Women were asked with a yes/no response if they had a
mammogram within the past three years (ADHERENT)
or whether they had exceeded the three-year frequency
(NON-ADHERENT). Furthermore, they were asked to
identify the location of their mammogram if they had
undergone the screening test recently.
Statistical analysis
Throughout the analyses, basic statistics were presented
through the use of mean values or percentages. A Chi-
square test was used to test for any significant associations
between two categorical variables. The Shapiro-Wilk test
was applied on all 14 constructs to determine whether
these variables are normally distributed. Since only the
variable (Causes of BC) was normally distributed, the
Independent Samples t-test (parametic test) was used for
the latter construct to compare two independent samples,
while the Mann-Whitney test was used for the non-
normal distributed variables (non-parametric test) i.e. for
all the other 13 constructs which were not normally
distributed (p < 0.001). Missing data was minimal and re-
ported in our previous paper [13]. Statistical significance
was established at p < 0.05 for all analyses.
Results
Sample characteristics
The mean age was 54.6 years ±2.8 years (SD). A table pre-
senting the sample characteristics for the total sample (n
= 404) is available in our previous published paper [13]).
Mammography screening practices
Figure 1 presents the mammography screening practices
by Maltese women. From the total sample of 404
women, 80.2% (n = 324) had a recent mammogram (AD-
HERENT), 5.9% (n = 24) had exceeded the three-year
frequency (NON-ADHERENT) and 13.9% (n = 56) never
had a mammogram.
Out of the 404 women, 60.1% (n = 243) attended the
MBSP and 39.9% (n = 161) did not. Out of 39.9% (n =
161) of women who did not undergo a mammogram at
the MBSP, there were 65.2% (n = 105) who underwent
mammography elsewhere (at a private practice), of
which 82.9% (n = 87) had a mammogram within three
years (ADHERENT) while 17.1% (n = 18) had a mammo-
gram that exceeded the recommended regular three-year
frequency (NON-ADHERENT).
Fig. 1 Mammography use in Malta
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Out of the 60.1% (n = 243) of women who underwent
a mammogram at the MBSP, 97.5% (n = 237) had a re-
cent screening mammography at the MBSP (ADHER-
ENT), while 2.5% (n = 6) exceeded the three-year
frequency (NON-ADHERENT). When applying a Chi-
square test to compare NON-ADHERENCE to private
practice versus NON-ADHERENCE to MBSP (17.1%
versus 2.5%), this result was found to be significantly as-
sociated (χ2 = 24.6, p = 0.000).
Those who never attended for mammography any-
where (n = 56) were excluded from this analysis as this
group was already analysed in further detail in our previ-
ous published paper on lifetime mammography use [63].
ADHERENT versus NON-ADHERENT subgroup analyses
Chi-square tests were performed to explore associations
between ADHERENT and NON-ADHERENT attenders
and the following variables: sociodemographic factors,
health status, knowledge, health beliefs and illness
perceptions.
Sociodemographic characteristics and health status
No significant associations were found between ADHER-
ENT or NON-ADHERENT women in relation to socio-
demographic or health status variables (p > 0.05).
Knowledge of breast screening frequency
Knowledge of BS frequency was significantly associated
with women’s adherence to mammography screening
(χ2 = 5.5, p = 0.020). The main difference arises from
those who said they were ‘unsure’ about the recom-
mended frequency, where 12.5% of the non-adherent
group were unsure about the recommended BS fre-
quency while only 3.1% of the adherent group were un-
sure of the recommended time interval.
Health beliefs
Some sub-scale items for perceived barriers and cues to
action were found to be statistically significant (p < 0.05)
when comparing adherent versus non-adherent women
(Table 1). Non-adherent women were undecided on the
following items when compared to adherent women: ‘hav-
ing a routine mammogram would make you anxious
about BC’ (p = 0.040), ‘if your GP advises you to attend,
you will attend’ (p = 0.038), ‘hearing about BC and BS in
the media or news makes you think about getting a mam-
mogram’ (p = 0.030), or ‘reminder letters’, ‘reminder phone
calls or text messages’ would help you to get a mammo-
gram’ (p = 0.000 respectively). Women who fear or dis-
trust the medical team (p = 0.003) or who feel they have
too many other problems in life (p = 0.001) tend to attend
less frequently. Women who do not agree that reminder
letters, reminder phone calls or text messages would help
them to get a mammogram (p = 0.000 respectively) also
tend to attend less frequently to mammography.
Illness perceptions
Women who are undecided on the following subscale
items attend less frequently for mammography: ‘your
mental attitude’ (p = 0.008), ‘family problems or worries’
(p = 0.035), your emotional state’ (p = 0.000), ‘your per-
sonality’ (p = 0.006), and ‘you get anxious when you
think about BC’ (p = 0.044) (Table 2). Mann Whitney
test and Independent Samples t-test were applied to
compare ‘ADHERENT’ and ‘NON-ADHERENT’ mam-
mography use against all 14 constructs, showing a statis-
tically significant difference in perceived barriers and
cues to action (p = 0.000, p = 0.039 respectively) between
adherent and non-adherent women (Table 3).
The findings show that for women who were NON-
ADHERENT to the three-year time frequency for mam-
mography use perceive higher barriers and lower cues to
action than ADHERENT women.
Discussion
This study made possible an understanding of the deter-
minants of timely BS behaviour in Malta which may aid
the development of evidence-based and culturally-
sensitive interventions for the Maltese population. Our
findings show that women who have previously partici-
pated in BS practices may already understand the screen-
ing benefits for BC, have come to terms with barriers to
undergo mammography, and have confidence in their
abilities to get screened [2] and thus attend for mammog-
raphy at the recommended time intervals. Similarly, find-
ings by Moodi et al. [64] suggest that women who
previously had at least one mammogram in their lifetime
had higher levels of health motivation, perceived benefits,
and perceived self-efficacy to mammography screening
and fewer perceived barriers to having a mammogram.
This further proves that previous mammography use
strongly predicts subsequent screening [2, 14, 64].
Our study showed that there were some Maltese
women who did not attend for mammography in a
timely manner. In terms of (self-initiated) behaviour with
mammography, this could be due to the fact that not all
women may view this as a positive action to improving
health outcomes. Identifying attributes of non-attending
women to regular time intervals entails going beyond
demographic differences to reveal complex interactions
among personality attributes. Consistent with Cham-
pion’s Health Belief Model and Leventhal’s Common-
Sense Model of self-regulation, it was the ‘perceived
barriers’ and ‘cues to action’ constructs that emerged as
the strongest predictors to describe the variance between
the ADHERENT and NON-ADHERENT groups. Hence,
women who attend at longer intervals may need to
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overcome barriers to seeking mammography and follow
tailored cues to action in order to attend at recom-
mended time intervals.
A plausible explanation for the disappearance of an
effect of socio-demographic factors in our subgroup ana-
lyses on adherence in this study is that they represent
‘carriers’, as described by Lagerlund [65], of already estab-
lished health-related behaviours. This is evidence in all
our studies on first invitation to MBSP [13], re-attendance
[14] and lifetime mammography use [63], where different
socio-demographic and health status variables were non-
significant predictors of uptake to mammography
screening.
Literature suggests that having a breast condition or
symptoms increase the use of mammography [66, 67] but
this factor has not been found consistently in all studies
[27, 68] and similarly, not in this study on timely mam-
mography adherence. These results can indicate trust in
the health care system and positive cancer experiences
such as family members or close friends surviving cancer,
but this issue needs further attention, preferable in quali-
tative research.
In all our data analyses, knowledge of the BS frequency
was found to be significantly associated with MBSP at-
tendance [13], re-attendance [14], lifetime screening [63]
Table 1 Health Belief items
ADHERENT versus
NON-ADHERENT
Health Beliefs χ2 p-value
There is no possibility of getting breast cancer (r) 5.5 0.239
Your chances of getting breast cancer are high 0.3 0.960
There may be the possibility of developing breast
cancer in your lifetime
7.8 0.055
When you get a mammogram, you feel good about
yourself
5.9 0.115
When you get a mammogram, you do not worry
as much about breast cancer
3.6 0.302
Having a mammogram will help you find lumps
early in your breasts
0.9 0.819
If you find a lump through a mammogram, the
treatment for breast cancer may not be as bad
0.7 0.863
Having a mammogram will decrease your chances
of dying from breast cancer
1.2 0.744
Having a mammogram will help you find a lump
before it can be felt by yourself or a health
professional
1.5 0.676
Having a routine mammogram would make you
anxious about breast cancer
8.3 0.040*
Having a routine mammogram would make you
worry
3.2 0.522
You fear having a mammogram because you
might find out that something is wrong
5.3 0.257
You fear having a mammogram because you do
not know the procedure or what to expect
2.8 0.418
You fear having a mammogram because you
know someone (family or friend) with breast cancer
7.0 0.136
It is embarrassing for you to have a mammogram 6.0 0.055
Undergoing mammography will be painful or
uncomfortable
3.8 0.284
Having a mammogram is time consuming 2.7 0.258
You are discontent with Breast Screening personnel
as they have been rude to you
n/a n/a
You have fear or distrust in the medical team 13.9 0.003*
Having a mammogram would expose you to
unnecessary radiation
4.7 0.197
You have too many other problems in your life
than to get a mammogram done
14.9 0.001*
You are not old enough to have a mammogram
periodically
0.4 0.823
If your GP advises you to attend for a mammogram,
you will attend
8.4 0.038*
If your relatives or friends advise you to attend for
a mammogram, you will attend
1.3 0.741
If someone close to you has been diagnosed with
breast cancer, you will attend for a mammogram
3.2 0.362
Hearing about breast cancer and breast screening
in the media or news makes you think about
getting a mammogram
8.9 0.030*
Reminder letters would help you to get a
mammogram
20.9 0.000*
Table 1 Health Belief items (Continued)
ADHERENT versus
NON-ADHERENT
Health Beliefs χ2 p-value
Reminder phone calls or text messages
would help you to get a mammogram
20.9 0.000*
Routine educational talks regarding breast
cancer awareness would help you to get
a mammogram
6.7 0.820
You feel confident that if you had a
mammogram done, any abnormalities in
your breasts will be detected
4.7 0.318
You can arrange other things in your life
to get a mammogram
1.5 0.821
In case you need a mammogram, you
will find a place to get it done
1.8 0.752
You can make an appointment for a
mammogram
1.7 0.800
You can arrange transportation to get
a mammogram
1.6 0.812
You can talk to people at the breast
screening centre about your concerns
n/a n/a
You can find a way to pay for a
mammogram if you need to
2.3 0.511
(r) = reverse scored
*Significant at α = 0.05
Chi-square test was applied for all health beliefs; hence the categorical
answers were used to apply this test for association. For each question,
respondents were asked to select a number between 1 and 5, where 1 =
strongly disagree and 5 = strongly agree. For certain items, responses were
re-grouped to ensure the feasibility of the Chi-square test
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and likewise in this study on timely mammography
adherence, showing that women who were unsure
were less likely to attend for a mammogram at rec-
ommended intervals. Ritvo et al. [19] expands on
such data, showing that it becomes more consequen-
tial with findings that the belief about recommended
screening intervals predicts screening adherence in
women with a family history of BC. Our findings are
consistent with studies that examined the relationship
in average risk women over 50 years where women
who reported screening according to the respective
national guidelines were significantly more likely to
adhere than women who reported less frequent time
intervals [19, 69, 70]. Our results underscore the
significance of communicating and reiterating a
screening interval recommendation to women such
that they develop strong beliefs about the need to
screen at that recommended time interval.
Table 2 Illness Perception items
ADHERENT versus
NON-ADHERENT
Illness Perceptions χ2 p-value
The presence of a lump or thickening in
the breast
3.2 0.361
Nipple discharge 4.1 0.254
Sudden nipple retraction 7.0 0.072
Change in shape or appearance of the
nipple
7.9 0.052
Breast swelling, dimpling, redness or
soreness of the skin
3.6 0.305
Skin changes of the breast 4.7 0.193
A sudden change in breast size 1.5 0.682
Aching breasts 6.2 0.185
Stress or worry 2.8 0.250
Your mental attitude (e.g. thinking about
life negatively)
12.0 0.008*
Family problems or worries 6.7 0.035*
Overwork 7.5 0.057
Your emotional state (e.g. feeling down,
lonely, anxious, empty)
22.0 0.000*
Your personality 12.3 0.006*
Hereditary - it runs in the family 3.2 0.360
Diet or eating habits 1.9 0.590
Poor medical care in the past 1.4 0.699
Your own behaviour 3.8 0.282
Ageing 0.8 0.663
Smoking 0.5 0.927
Alcohol 0.0 0.979
A germ or virus 2.9 0.234
Pollution in the environment 2.8 0.428
Altered immunity 0.4 0.933
Chance or bad luck 1.0 0.908
Accident or injury 1.2 0.875
Breast cancer will last a short time 0.6 0.904
Breast cancer is likely to be permanent
rather than temporary
4.8 0.089
A patient with breast cancer goes through
cycles in which her illness gets better and
worse
1.6 0.800
Breast cancer has major consequences
on a patient’s life
2.1 0.559
Breast cancer will not have much effect
on your life
2.4 0.662
Breast cancer would strongly affect the
way others see you
4.4 0.351
Breast cancer has serious economic and
financial consequences
0.8 0.840
Breast cancer would strongly affect the
way you see yourself as a person
2.7 0.446
Table 2 Illness Perception items (Continued)
ADHERENT versus
NON-ADHERENT
Illness Perceptions χ2 p-value
Breast cancer would threaten a relationship
with your husband or partner
3.6 0.461
If you had breast cancer, your whole life
would change
0.6 0.902
If you developed breast cancer, the
chances of living a long life would decrease
0.8 0.844
There is a lot which you can do to control
the symptoms if Breast Cancer occurs
1.3 0.869
The course of Breast Cancer will depend
on your actions
1.7 0.646
Your actions will have an effect on the
outcome of Breast Cancer
1.1 0.787
There is no treatment that will help to
improve Breast Cancer
4.0 0.406
The treatment provided will be effective in
controlling or curing Breast Cancer
0.5 0.926
The negative effects of Breast Cancer can
be prevented or avoided by the treatment
given
1.0 0.914
You have a clear picture and understanding
of Breast Cancer
2.6 0.455
Breast Cancer is a mystery to you 1.7 0.786
You get anxious when you think about
Breast Cancer
8.1 0.044*
Breast Cancer makes you feel afraid 0.7 0.875
You get worried when you think about
Breast Cancer
0.7 0.871
*Significant at α = 0.05
Chi-square test was applied for all health beliefs; hence the categorical
answers were used to apply this test for association. For each question,
respondents were asked to select a number between 1to 5, where 1 = strongly
disagree and 5 = strongly agree. For certain items, responses were re-grouped
to ensure the feasibility of the Chi-square test
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In some countries with dual public and private screen-
ing programmes, there is only partial understanding of
adherence. Women who were active in opportunistic
screening, for instance, are considered non-compliant to
the screening programme [27]. Moreover, varying
patterns of opportunistic screening exist (differing age
groups, sometimes single view mammography) [71], in-
cluding varying screening intervals such that women’s
last mammography may have been longer than the
recommended screening guidelines [9, 72].
The reasons why women chose to opt for private
mammography rather than to the organized programme
are not yet fully understood. This may be due to women
seeking BS at a younger age (30–49) as a precautionary
measure [20] and continue to sustain early detection
practices in this way. Evidence from the U.S. National
Health Interview Survey revealed that 29% of women
aged 30–39 have undergone mammography [73] while
data from the 2010 Behavioural Risk Factor Surveillance
Study showed that 83% of women aged 40–49 have had
BS [74]. Hence, public health strategies and wide media
coverage directed at convincing older women to engage
in BS may arouse a positive attitude among younger age
groups towards early detection practices [75, 76] or may
induce anxiety and fear of BC and mortality, motivating
younger women, particular those aged 40–49, to engage
in mammography screening [20].
The balance of benefits and harms remains to date a
strongly debated topic in the field of population-based
BS [77]. Although the usually considered benefits from
BS include avoiding deaths from BC, achieving less
invasive treatments and improving quality of life, there
is growing concern that mammography may be overused
(overscreening) [78], or screening may result in the de-
tection by screening of BCs that would never have come
to clinical attention (overdiagnosis) [79] and thus
women receiving treatment for a slow growing or non-
invasive cancer which would have unlikely caused any
problems if left untreated [80]. Given the lack of reliable
evidence, an independent expert panel estimated that
around 1 in 4 women (or 4000 out of around 15,500
women) are overdiagnosed in the UK [81]. This is
coupled with the side-effects and anxiety that anyone
having cancer treatment goes through. Moreover, ex-
perts estimate that for every 10,000 women who have
regular three-year screening between 47 and 73 years in
the UK, there will be between 3 to 6 extra BCs caused
by radiation [81]. Notwithstanding, the recent IARC
Working Group [79] found sufficient evidence of a
reduction in BC mortality through mammography
screening in women aged 50–74 years, to the extent that
the benefits substantially outweigh the risk of radiation-
induced cancer and of overdiagnosis. Moreover, the
survival rate of patients with early-detected BC through
routine screening is approximately double that from de-
tected cancers through other methods [81]. Unlike con-
sistent mortality reductions reported through organised
screening programmes [82], there is yet no direct evi-
dence to support the effectiveness of opportunistic
screening [83, 84].
Our results suggest that those attending an organised
screening programme such as, the MBSP, are more likely
Table 3 Comparisons between the frequency of mammography use and health beliefs/illness perception constructs
ADHERENT
(n = 324)
NON-ADHERENT
(n = 24)
Test Statistic p-value
Perceived Susceptibility M = 9.6, SD = 1.0 M = 9.4, SD = 0.9 3641.0a 0.577
Perceived Benefits M = 24.0, SD = 1.8 M = 23.9, SD = 1.3 3515.0a 0.387
Perceived Barriers M = 27.2, SD = 4.7 M = 31.1, SD = 5.0 5540.5a 0.000*
Cues to action M = 27.4, SD = 3.2 M = 26.0, SD = 3.5 2919.0a 0.039*
Self-Efficacy M = 24.8, SD = 2.7 M = 24.5, SD = 2.1 3666.5a 0.615
Breast Cancer Identity M = 30.6, SD = 2.1 M = 30.3, SD = 3.4 4136.5a 0.582
Causes of Breast Cancer M = 55.9, SD = 7.2 M = 57.0, SD = 6.9 -0.7b 0.467
Cancer Timeline: Acute/Chronic M = 6.1, SD = 0.9 M = 5.9, SD = 1.0 3515.5a 0.402
Cancer Timeline: Cyclical M = 3.6, SD = 0.7 M = 3.7, SD = 0.6 4271.0a 0.327
Consequences M = 28.2, SD = 2.5 M = 28.5, SD = 2.7 4247.5a 0.446
Personal Control M = 11.8, SD = 0.8 M = 11.9, SD = 0.6 3905.5a 0.951
Treatment Control M = 9.9, SD = 0.7 M = 10.0, SD = 0.5 4166.5a 0.397
Illness Coherence M = 6.9, SD = 1.2 M = 7.3, SD = 0.9 4538.0a 0.139
Emotional Representations M = 12.2, SD = 2.1 M = 12.7, SD = 1.8 4348.0a 0.320
*Significant at α = 0.05
aMann Whitney test
bIndependent Samples t-test
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to adhere to recommended time intervals when compared
with those attending the private sector for screening. In
order to reach greater adherence to recommended time
intervals, women should receive further information on
the recommended screening frequency and the benefits of
being part of an organised programme [31, 85]. For ex-
ample, in Malta, private screening does not have the same
quality controls as the MBSP such as higher quality of
mammographic interpretation through special training of
the readers and mammographers, double-reading and
consensus reads [71]. For instance, a mammogram in
organised screening is read by two radiologists, who inter-
pret at least 5000 screening mammograms a year. This is
the recommended volume set by the European Guidelines
for Quality Assurance in Breast Cancer Screening [30, 82,
84–86] and the desirable individual level of experience set
in the United Kingdom [87]. Moreover, based on a similar
screening context as our local system, other studies raise
awareness that organized screening leads to inequality
reductions, higher quality assurance, and more timely
screens than opportunistic screening [27, 71, 83, 88].
While private screening remains unregulated, quality
cannot be guaranteed which is why national screening
programmes are recommended [71, 89]. Therefore, a
key benefit of a national screening programme is that
women can be individually monitored to ensure that
they are conformant with screening guidelines and that
they are adequately monitored in terms of robust quality
assurance measures.
Strengths and limitations
Although this study was limited to the Maltese setting,
much of the developed world has organised breast
screening programs and access to the same body of
scientific evidence, and thus the findings are likely to be
broadly applicable across these countries. However, we
found no study that has similarly and simultaneously
assessed sociodemographic and psychological variables
as predictors of timely attendance and specifically at-
tendance at organized or opportunistic screening. We
also found none which utilised HBM and CSM as the
theoretical framework. The major strength of this study
is the rich dataset which allowed us to analyse diverse
subgroups. However, this is not without possible re-
sponse bias as a source of possible weakness. Since this
study was cross-sectional, it precludes looking at cause-
and-effect relationships over time. While a Chi-square
test showed that women who attend private screening
were less likely to be regulated in their attendance when
compared to MBSP attendees, it cannot be ruled out
that women attending private screening would be less
likely to attend screening regularly even if they attended
MBSP. This could be due to the characteristics of the
women attending private screening. Although screening
attendance was confirmed through screening records,
our records of private mammography were self-reported
and hence, subject to bias. Self-reported data could also
have affected the observed difference between women
attending private screening and the MBSP. Objective
measurement would require data from private clinics,
which was not possible to obtain, since no data records
from private screening in Malta are nationally available to
date. As a first step, it would be necessary to identify reli-
able and validated measures for regular mammography
use that can be used simultaneously in government
organised and private screening programmes. While lim-
ited studies to date have been of sufficient dimension to
provide results on irregular attendance [16], qualitative
studies would contribute towards understanding why
health beliefs influence adherence.
Conclusions
Our results suggest that attendance at an organised BS
programme improves adherence to recommended time
intervals when compared with those attending the
private sector for screening. In order to reach greater ad-
herence to recommended time intervals, women should
be made more aware of the recommended screening
frequency and on the benefits of being part of an orga-
nised programme. Women can be individually monitored
through the national screening programme to ensure that
they are conformant with screening guidelines. Screening
programmes should target women’s health beliefs, in par-
ticular perceived barriers and cues to action, which have
emerged as the most important factors to distinguish
between adherent and non-adherent women to improve
adherence to recommended time intervals. Further quali-
tative research is required to understand in more depth
why women choose opportunistic screening over an
organised programme.
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